SenzaGen Group aims to be a leader in in vitro science and testing, driving the transition from animal testing to methods better suited to reflect human biology.

We provide high-performance, non-animal test methods and innovation and advisory services based on state-of-the-art technology. Non-animal methods are more effective, more accurate and less expensive than traditional animal-based methods while also helping to reduce the number of laboratory animals.

SenzaGen is listed on Nasdaq Stockholm (SENZA).